Invasive pneumococcal disease is a significant health burden in Australia, with immunisation recommended for children and at-risk adults. Health benefits of immunisation are clear, but less effective when immunisation rates are low, as in Western Australia. We hypothesised that patients admitted unplanned to the intensive care unit (ICU) would have high eligibility for pneumococcal immunisation, but low rates of recorded vaccine administration. We performed a prospective observational study of 119 emergency admissions to Royal Perth ICU, a 20-bed mixed ICU at a tertiary teaching hospital in Western Australia. Each admission was screened for vaccine eligibility (age and risk factors as per Australian Technical Advisory Group of Immunisation guidelines), with patients' health records examined and primary care providers contacted after ICU discharge. Risk factors for invasive pneumococcal disease were common, with 52% of the study population having one or more. Fifty-four of 119 admitted patients (45%) were assessed as eligible for immunisation after ICU discharge. ICU survivors represent a highrisk population for which intervention against modifiable targets, such as invasive pneumococcal disease, may reduce both their chronic health burden and future health expenditure. Future efforts should concentrate on assessing the feasibility of a screening program for modifiable factors in ICU survivors, and the logistics of delivering these interventions in a timely manner during their hospital stay.
Invasive pneumococcal disease (IPD) is caused by the bacterium Streptococcus pneumoniae and results in conditions such as bacteraemia, pneumonia and meningitis. IPD has been a notifiable disease in Australia since 2001, with 1,823 cases (8.0 per 100,000) of IPD, and 126 deaths attributable to IPD, notified to the National Notifiable Diseases Surveillance System in 2012. It should be noted that deaths are likely to be under-reported 1 . In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children and at-risk adults including those aged 65 years or older (with potential for an additional dose after five years in those older than 65 years with IPD risk factors), Aboriginal and Torres Strait Islanders over 50 years, and for high-risk Indigenous patients (including smokers) between 15 years and 49 years 2 . In 2012, 621 cases were reported in adults aged 65 years or over, representing a rate of 19.3 per 100,000. In this age group, there were 88 deaths associated with IPD, giving a case fatality rate of 14.2%. Of those deaths, 59% (52/88) in 2012 were attributable to a stereotype included in the 23 valent pneumococcal vaccine (Pneumovax 23) 1 . Administration of Pneumovax 23 to high-risk groups and the elderly has been shown to significantly reduce the incidence of IPD 3 , as well as pneumococcal pneumonia incidence and mortality [4] [5] [6] , but benefits may be modest without increasing coverage of the target population in Australia 3 . There is currently no dedicated national immunisation register for adults or children over seven years in Australia, but telephone surveys suggest falling vaccination uptake rates since 2007 in people older than 65 years, with four in ten adults eligible for pneumococcal vaccination having never been immunised 7 . Vaccination status in Australia varies geographically, with more than 48% of over-65-year-olds in Western Australia thought to be currently unvaccinated 7 . An admission to an intensive care unit (ICU) presents an opportunity for identifying eligible patients for revaccination, screening patients' vaccination status and a possible intervention (administration of Pneumovax 23) for unvaccinated eligible adults. This may be a particularly relevant opportunity for intervention with high-risk patients who may not have regular contact with the healthcare system and are at higher risk of IPD 8, 9 . This concentration of high-risk individuals, coupled with likely prolonged hospital stays and involvement of multiple specialist teams makes screening in ICU, with vaccine administration and follow-up during the subsequent post-ICU hospital stay, an attractive proposition 10 .
A United States study looking at pneumococcal immunisation candidacy (for Pneumovax 23) in ICU patients suggested a high rate of eligibility, but an extremely low rate of recorded vaccination status or administration of pneumococcal vaccine during the index stay 11 . We hypothesised that, in patients admitted emergently to an ICU, eligibility for Pneumovax 23 immunisation would be high, but that documented current full vaccination status would be low.
Our aim was to conduct a prospective observational study of emergency admissions to our ICU to examine potential eligibility for vaccination with Pneumovax 23 in this cohort.
Materials and methods
We carried out a single centre prospective observational study of emergency admissions to the 20-bed mixed ICU at Royal Perth Hospital, a tertiary teaching hospital in Western Australia, between 22 November 2014 and 12 April 2015.
Convenience sampling was used, with screening concurrent with availability of researchers. Emergency admissions were chosen to enrich the cohort with risk factors for IPD. For each emergency admission, a screening procedure was carried out to assess eligibility for Pneumovax 23 vaccination as per the Australian Technical Advisory Group of Immunisation (ATAGI) guidelines ( Figure 1 and Table 1 ). After ICU discharge, patients identified as potentially eligible had their health record examined and their general practitioner (GP) or Aboriginal Health Service worker contacted for evidence of prior vaccination. If available, vaccination information was collected including last pneumococcal vaccine administration and total number of recorded vaccine doses.
Patients were assessed as eligible for Pneumovax 23 during this hospital admission if they met initial criteria in terms of age, race and risk factors and could not be confirmed as current with an immunisation program. Patients in whom no immunisation history could be obtained were assessed as eligible.
Information on patient demographics was collected such as age, gender, ethnicity, ICU admission diagnosis, ICU and hospital length of stay (LOS), death in ICU or hospital, and organ support therapies. 
Results
Between 22 November 2014 and 12 April 2015 there were 682 admissions to the ICU, including 537 patients admitted emergently. Of these, 119 patients were screened and included in the study. Characteristics of the patient population can be seen in Table 2 .
The studied population of unplanned admissions was relatively typical for a tertiary ICU, with a mean Acute Physiology and Chronic Health Evaluation (APACHE) III score of 68.75 (SD ±33.29). During their ICU stay, 89 (74.7%) patients received invasive ventilation, and 16 (13.4%) received renal replacement therapy.
Median ICU LOS was 93 hours (interquartile range, IQR 44 to 197 hours), with a median hospital LOS of 249 hours (IQR 121 to 552 hours). The demographic characteristics of the study population are provided in Table 2 .
There were 15 deaths in the ICU (ICU mortality rate of 12.6%) with 18 by hospital discharge, giving an in-hospital mortality of 15.1% for our studied population.
Risk factors for IPD
Over half of the study population (52%) had one or more risk factors for IPD, with tobacco smoking, chronic lung disease and chronic cardiac disease the most common (see Table 2 ).
Eligibility for vaccination
Forty-five percent of our total study population was assessed as eligible for immunisation.
Of the study cohort, 63 patients met criteria for vaccination eligibility and had their immunisation histories examined for evidence of vaccination status (hospital medical records, primary care contacted), with 56 patients excluded on the basis of age and lack of risk factors (as per current ATAGI guidelines).
Forty-six of these 63 patients had a documented immunisation record, with only nine having current full pneumococcal immunisation documented.
None of the potentially eligible patients received immunisation in hospital, or had mention made of immunisation status in discharge documentation.
Discussion
Our study shows that the incidence of patients at risk of IPD amongst emergency admissions to intensive care was high, with over half of the 119 patients having specific risk factors for IPD. Of the cohort fulfilling eligibility for administration of Pneumovax 23, only 55% had documentation of current vaccination, suggesting low rates of current immunisation despite substantial recent contact with the healthcare system in many cases. Table 1 Risk factors predisposing adults to invasive pneumococcal disease • Asplenia, either functional (including sickle cell disease) or anatomical.
• Conditions of impaired immunity associated with an increased risk of IPD, e.g. HIV infection, acute nephrotic syndrome, multiple myeloma, lymphoma, Hodgkin's disease and organ transplantation.
• Chronic illness associated with an increased risk of IPD including chronic cardiac, renal or pulmonary disease, diabetes, and alcohol-related problems.
• CSF leak.
• Tobacco smokers.
IPD, invasive pneumococcal disease; HIV, human immunodeficiency virus; CSF, cerebrospinal fluid. Awareness of the effect of chronic illness on long-term morbidity and mortality for ICU survivors has greatly increased over the past 10 years 12, 13 . Emergent admission to ICU is a strong predictor of subsequent critical illness 14 ; both the acute care costs and future costs related to worsening chronic health burden in this cohort are high 15 . The health economics would seem to strongly support making all reasonable efforts to improve modifiable health factors in this population 16 . The ICU holds a number of distinct advantages for identification of modifiable long-term health factors. Firstly, it caters to a unique population of high-risk patients, who often have significant comorbidities, hence may provide more value for money when screening for modifiable factors. This ICU population is more likely to be eligible for immunisation due to age and risk factors, and also poses a greater potential cost to the health service, due to more frequent admissions and longer lengths of stay, offering greater savings if these can be avoided. Secondly, the ICU may be more suitable than a ward environment for screening due to the prolonged period spent in one area and greater opportunities for contact with GPs and family members providing accurate collateral history (including immunisation history). Thirdly, for many rural or itinerant patients, particularly Indigenous patients, an ICU admission may represent a rare contact with the health service. This opportunity to reduce these patients' long-term health burden should be exploited judiciously. Lastly, from a technical standpoint, screening for vaccination eligibility or other modifiable risk factors should be easily amenable to automation. The ICU is an area highly likely to be prioritised within the hospital for electronic clinical information systems. These systems should allow for simple automated screening of all ICU patients, with eligible patients being automatically flagged for further action 17 . While the ICU represents a unique opportunity for screening high-risk patients, it is not the ideal time to administer vaccines. Pneumococcal vaccination following emergency splenectomy occurs after ICU discharge, but before hospital discharge, and this may be the optimal time to also vaccinate other cohorts identified as at-risk for IPD. Elective admissions to ICU would ideally be screened and immunised (if appropriate) via a pre-admission clinic, as part of the patient's preoperative medical optimisation.
Limitations
Our study was conducted in a single, larger tertiary ICU and the results may not be generalisable to smaller ICUs or those in different geographical areas. Convenience sampling was utilised due to resource limitations, raising the potential for selection bias. However, as the major referral centre for emergency ICU admissions within Western Australia, the cohort is likely to be representative of this demographic.
The study examined the number of patients admitted to ICU who would be potentially eligible for Pneumovax 23 on discharge, but not the cost effectiveness of such a program. Future studies should assess the feasibility and cost-effectiveness of an ICU screening program for modifiable factors, such as vaccination for pneumococcal and influenza infections. A small number of study participants had no immunisation record obtainable from primary healthcare providers (GPs, clinics, remote area nurses or Aboriginal Health workers) or available health records, and were hence recorded as eligible for pneumococcal immunisation. However, it is unlikely that this substantially overestimates the number eligible for vaccination, as the proportion was low (17%), and is consistent with published Western Australian immunisation rates 7 . Finally, our study did not examine implementation of a vaccination program in those identified as high risk, and the proportion of eligible patients who may decline vaccination or have ongoing contraindications to vaccination requires further evaluation.
Conclusion
Over half of all patients with an unplanned admission to ICU have risk factors for invasive pneumococcal disease and 45% fulfil eligibility for vaccination. Despite this, a substantial proportion did not have documentation of current vaccination status. ICU survivors represent a high-risk population for which intervention against modifiable targets such as invasive pneumococcal disease may reduce both their chronic health burden and future health expenditure.
Future efforts should concentrate on assessing the feasibility of a screening program for modifiable factors in ICU survivors, and the logistics of delivering these interventions in a timely manner during their hospital stay.
